← All organizations
Highest phase reached
Phase 4
First clinical trial
Oct 1, 2000First marketed drug
Jun 23, 2006First NDA
Jun 23, 2006Last known activity
Feb 1, 2012
Acquired by Johnson and Johnson on Jan 1, 2002
Timeline
1990s
- Jan 1, 1994
Tibotec— Founded
2000s
- Jan 1, 2002
Johnson and Johnson— Acquired By
- Jan 18, 2008
etravirine— NDA Organization
Drugs by trial phase (61 distinct, 129 trials)
Phase 4 (9 own, 0 via acquisition)
Phase 3 (12 own, 0 via acquisition)
Phase 2 (13 own, 0 via acquisition)
Phase 1 (27 own, 0 via acquisition)
Indications
Approved for
Studied for
- Acquired Immunodeficiency Syndrome
- Breast Neoplasms
- Communicable Diseases
- Disease
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- Hepatitis, Chronic
- HIV Infections
- Hyperlipidemias
- Immunologic Deficiency Syndromes
- Infections
- Inflammation
- Insulin Resistance
- Kidney Diseases
- Liver Diseases
- Lymphoma
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Multiple Myeloma
- Mycoses
- Neoplasms, Plasma Cell
- Opioid-Related Disorders
- Tuberculosis
Marketed drugs (2)
Recent trials (50)
- NCT01485991Study directorPhase 3Feb 1, 2012
- NCT01423812CollaboratorPhase 4Jan 1, 2012
- NCT01486004Lead sponsorPhase 1Nov 1, 2011
- NCT01486004Study directorPhase 1Nov 1, 2011
- NCT01479881Study directorPhase 1Oct 1, 2011
- NCT01479881Lead sponsorPhase 1Oct 1, 2011
- NCT01381835Study directorPhase 1Jul 1, 2011
- NCT01381835Lead sponsorPhase 1Jul 1, 2011
- NCT01391117Lead sponsorPhase 1Jun 1, 2011
- NCT01391117Study directorPhase 1Jun 1, 2011
- NCT01308606Study directorPhase 1Mar 1, 2011
- NCT01336829Study directorPhase 1Mar 1, 2011
- NCT01323257Lead sponsorPhase 1Mar 1, 2011
- NCT01308606Lead sponsorPhase 1Mar 1, 2011
- NCT01336829Lead sponsorPhase 1Mar 1, 2011
Details
- Founded
- Leuven, BE Jan 1, 1994
- First NDA
- Jun 23, 2006
- Last known activity
- Feb 1, 2012
Designations held
- Fast track
- Priority review
- Accelerated approval
Notes
Acquired by Johnson and Johnson